Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
No description.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
